H. Lundbeck A Logo

H. Lundbeck A

HLUN | CO

Overview

Corporate Details

ISIN(s):
DK0061804697 (+5 more)
LEI:
5493006R4KC2OI5D3470
Country:
Denmark
Address:
Ottiliavej 9, 2500 Valby
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

H. Lundbeck A/S is a global pharmaceutical company exclusively focused on brain diseases. With over 70 years of specialized expertise in neuroscience, the company is dedicated to the research, development, manufacturing, and commercialization of innovative treatments for psychiatric and neurological disorders. Lundbeck's core mission is to improve the quality of life for individuals living with conditions such as depression and post-traumatic stress disorder (PTSD). The company manages the entire value chain, from initial research to patient delivery, and markets its products in over 100 countries worldwide. It has developed and commercialized some of the world's most widely prescribed therapies for brain-related illnesses.

Social Media

Stop Scraping. Start Analyzing.

You're viewing a fraction of the data available for H. Lundbeck A. Get complete, real-time, and AI-ready data via the API the pros use.

Get Instant API & Bulk Data Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
2025-08-13 18:41
Interim Report
English 1.0 MB
2025-08-13 18:41
Earnings Release
English 32.1 KB
2025-08-13 18:35
Earnings Release
English 24.2 KB
2025-08-13 18:35
Earnings Release
English 129.5 KB
2025-02-21 13:27
Director's Dealing
English 124.1 KB
2025-02-21 13:27
Director's Dealing
English 29.9 KB
2025-02-05 16:40
Director's Dealing
English 134.1 KB
2025-02-05 16:40
Director's Dealing
English 96.6 KB
2025-02-05 07:46
Annual Report
English 6.4 MB
2025-02-05 07:46
Report Publication Announcement
English 2.9 KB
2025-02-05 07:46
Annual Report (ESEF)
English 13.1 MB
2025-02-05 07:24
Earnings Release
English 33.3 KB
2025-02-05 07:24
Earnings Release
English 443.0 KB
2025-02-04 17:11
Board/Management Information
English 17.0 KB
2025-02-04 17:11
Board/Management Information
English 99.1 KB

Automate Your Workflow. Get a real-time feed of all H. Lundbeck A filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for H. Lundbeck A via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
4BASEBIO PLC Logo
Manufactures GMP-compliant synthetic DNA for advanced therapies, vaccines, and cell/gene therapies.
United Kingdom 4BB
ABINGDON HEALTH PLC Logo
A CDMO for lateral flow rapid tests, providing end-to-end services and its own branded products.
United Kingdom ABDX
ABIONYX Pharma Logo
Biotech developing lipid-based therapies for rare renal and ophthalmological diseases.
France ABNX
AB Science Logo
Develops protein kinase inhibitors for oncology, neuro, and inflammatory diseases.
France AB
AcuCort AB Logo
Develops a rapid oral film for acute allergies, croup, and chemo-induced nausea.
Sweden ACUC
Advicenne Logo
Develops and commercializes therapies for rare renal diseases for patients of all ages.
France ALDVI
AegirBio AB Logo
Makes saliva-based diagnostics accessible for at-home & pro health & drug monitoring.
Sweden AEGIR
Aelis Farma Logo
Developing novel CB1 receptor inhibitors for treating brain and CNS disorders.
France AELIS
AGRONOMICS LIMITED Logo Isle of Man ANIC
ALK-Abelló Logo
Develops allergy immunotherapy (AIT) and emergency treatments for severe allergies.
Denmark ALK